Name | Title | Contact Details |
---|---|---|
Priya Sankar |
Associate General Counsel | Profile |
Chip Cale |
General Counsel | Profile |
Edgar Chip Cale |
General Counsel | Profile |
We are pioneering a better drug discovery process using systems biology to improve the lives of people with neurodegenerative disorders.
Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.
Our mission is to create tools that empower physicians and consumers by increasing their access to actionable data.
Pharmacists Mutual Companies is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.